Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats

European Journal of Pharmacology

Volumn 553, Issue 1-3, 2006, Pages 297-303

  Wang, Jinping ^a   Huang, Heqing ^a   Liu, Peiqing ^a   Tang, Futian ^a   Qin, Jia ^a   Huang, Wenge ^a   Chen, Fengying ^a   Guo, Fenfen ^a   Liu, Weihua ^a   Yang, Bing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Emodin; p38 mitogen activated protein kinase; Renal dysfunction

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EMODIN; FIBRONECTIN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY MASS; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ACTINS; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EMODIN; ENZYME INHIBITORS; FIBRONECTINS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; MALE; ORGAN SIZE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 33751172922     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.087     Document Type: Article

References (36)

1. Aggeli I.K., Caitanaki C., and Beis I. Involvement of JNKs and p38-MAPK/MSK1 pathways in H(2)O(2)-induced upregulation of heme oxygenase-1 mRNA in H9c2 cells. Cell. Signal. (2006) (Electronic publication ahead of print)
2. Bazuine M., Carlotti F., and Rabelink M.J. The p38 MAPK inhibitor SB203580 reduces glucose turnover by the glucose transporter-4 of 3T3-L1 adipocytes in the insulin-stimulated state. Endocrinology 146 (2005) 1818-1824
3. Begum N., and Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am. J. Physiol., Cell Physiol. 278 (2000) C81-C91
4. Bruno S., Cattaneo D., Perico N., and Remuzzi G. Emerging drugs for diabetic nephropathy. Expert Opin. Emerg. Drugs 10 (2005) 747-771
5. Chen H.M., Sachin B., Akanksha G., and Sharma A.C. Duration of streptozotocin-induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc. Diabetol. 4 (2005) 3-16
6. Collart F. Kidney failure, proteinuria, and diabetic nephropathy. Rev. Med. Brux. 24 (2003) A257-A262
7. Danda R.S., Habiba N.M., Rincon-Choles H., Bhandari B.K., Barnes J.L., and Abboud H.E. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int. 68 (2005) 2562-2571
8. De ́rijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., and Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
9. Fujita H., Omori S., Ishikural K., Hida M., and Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am. J. Physiol. Renal. Physiol. 286 (2004) F120-F126
10. Fujishiro M., Gotoh Y., Katagiri H., Sakoda H., Ogihara T., Anai M., Ono H., Funaki M., Inukai K., Fukushima Y., Kikuchi M., Oka Y., and Asano T. MKK6/3 and p38 MAPK pathway activation is not necessary for insulin-induced glucose uptake but regulates glucose transporter expression. J. Biol. Chem. 276 (2001) 19800-19806
11. Gilbert R.E., and Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int. 56 (1999) 1627-1637
12. Gruden G., Zonca S., Hayward A., Thomas S., Maestrini S., Gnudi L., and Viberti G.C. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 MAPK-dependent. Diabetes 49 (2000) 655-661
13. Ha H., and Kin K.H. Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C. Diabetes Res. Clin. Pract. 45 (1999) 147-151
14. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
15. Han Y.S., Bang O.S., Jin E.J., Park J.H., Sonn J.K., and Kang S.S. High dose of glucose promotes chondrogenesis via PKCalpha and MAPK signaling pathways in chick mesenchymal cells. Cell Tissue Res. 318 (2004) 571-578
16. Han S.K., Jeon S.J., Miyazawa K.., Yi S.Y., and Yoo Y.S. Enhancement of anti-inflammatory tendency by SB203580, p38 alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. Rheumatol. Int. (2006) (Electronic publication ahead of print)
17. Haneda M. Mechanisms for the development and progression of diabetic nephropathy. Nippon Rinsho 64 (2006) 427-432
18. Kang S.W., Adler S.G., Lapage J., and Natarajan R. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int. 60 (2001) 543-552
19. Kawano Y., Ryder J.W., Rincon J., Zierath J.R., Krook A., and Wallberg-Henriksson H. Evidence against high glucose as a mediator of ERK1/2 or p38 MAPK phosphorylation in rat skeletal muscle. Am. J. Physiol., Endocrinol. Metabol. Gastrointest. Physiol. 281 (2001) E1255-E1259
20. Koya D., Haneda M., Nakagawa H., Isshiki K., Sato H., Maeda S., Sugimoto T., Yasuda H., Kashiwagi A., Ways D.K., King G.L., and Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14 (2000) 439-447
21. Liu G., Ye R., and Tan Z. Effect of emodin on fibroblasts in lupus nephritis. Zhongguo Zhong Xi Yi Jie He Za Zhi 20 (2000) 196-198
22. McCarter R.J., Hempe J.M., and Chalew S.A. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 29 (2006) 352-355
23. Mcfalls E.O., Hon M., Bache R.J., Best A., Marx D., and Sikora J. Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium. Am. J. Physiol.: Heart Circ. Physiol. 287 (2004) H1328-H1334
24. Mei X.B., Yuan W.J., and Zhan F.L. Role of cyclin kinase inhibitor p27 in inhibition of emodin on mesangial cell proliferation induced by tumor necrosis factor-alpha. Zhong Xi Yi Jie He Xue Bao 2 (2004) 120-122
25. Meldrum K.K., Meldrum D.R., Hile K.L., Yerkes E.B., Ayala A., Cain M.P., Rink R.C., Casale A.J., and Kaefer M.A. p38MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. Am. J. Physiol., Cell Physiol. 281 (2001) C563-C570
26. Ning Y., Wang J., and Qu S. Effect of emodin on human kidney fibroblast proliferation. Zhongguo Zhong Xi Yi Jie He Za Zhi 20 (2000) 105-106
27. Russell T.A. Diabetic nephropathy in patients with type 1 diabetes mellitus. J. Nephrol. Nurs. 33 (2006) 15-28
28. Sakai N., Wada T., Furuichi K., Iwata Y., Yoshimoto K., Kitagawa K., Kokubo S., Kobayashi M., Hara A., Yamahana J., Okumura T., Takasawa K., Takeda S., Yoshimura M., Kida H., and Yokoyama H. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am. J. Kidney Dis. 45 (2005) 54-65
29. Singh L.P., Andy J., Anyamale V., Greene K., Alexander M., and Crook E.D. Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: the involvement of protein kinases A and C. Diabetes 50 (2001) 2355-2362
30. Song H., Wang Z., and Zhang F. Investigation of urinary interleukin-6 level in chronic renal failure patients and the influence of Rheum palmatum in treating it. Zhongguo Zhong Xi Yi Jie He Za Zhi 20 (2000) 107-109
31. Tomlinson D.R. Mitogen activated protein kinase as glucose transducers for diabetic complications. Diabetologia 46 (2003) 1271-1281
32. Tsiani E., Lekas P., Fantus I.G., Dlugosz J., and Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am. J. Physiol., Endocrinol. Metabol. Gastrointest. Physiol. 281 (2002) E161-E169
33. Valladares A., Alvarez A.M., Ventura J.J., Roncero C., Benito M., and Porras A. p38MAPK mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology 141 (2000) 4383-4395
34. Wang Y., Huang S., Sah VP., Ross Jr. J., Brown J.H., Han J., and Chien K.R. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen- activated protein kinase family. J. Biol. Chem. 273 (1998) 2161-2168
35. Wilmer W.A., Dixon C.L., and Herbert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int. 60 (2001) 858-871
36. Yuan Y., Wu Z.J., Yao H.Y., Yu X.D., Guo Z.K., Chen X.S., Tang P.X., and Mao N. Activation of p38 MAPK contribute to BMP4-induced alkaline phosphatase expression in MC3T3-E1 preosteoblast. Chin. Med. J. (Engl) 119 (2006) 324-327